Combined effect of alpha-methyldopa and a new enzyme inducer, Zixoryn, on the hepatic mixed-function monooxygenase system in humans.
Based on previous studies with alpha-methyldopa (inhibitor of hepatic mixed-function monooxygenase system) and m-trifluoromethyl-alpha-ethylbenzhydrol, a new enzyme inducer Zixoryn, the authors studied the effect of the combined treatment of the two compounds on the hepatic drug-metabolizing enzyme activity in ten patients. There was no change in antipyrine half-life and its apparent volume of distribution (aVd) in the amount of D-glucaric acid excreted in the urine (indirect parameters of the mixed-function monooxygenase system's activity) after 1-week administration of 1000 mg alpha-methyldopa together with 300 mg Zixoryn per day. The two compounds counteracted each other's effects in the applied doses.
D000328:Adult; D000368:Aged; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D004347:Drug Interactions; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D006801:Humans; D008099:Liver / Q000201:enzymology*; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000032:analysis*; D010088:Oxidoreductases / Q000032:analysis*
D001559:Benzhydryl Compounds; D008750:Methyldopa; D006899:Mixed Function Oxygenases; D010088:Oxidoreductases; C016914:flumecinol